How Does SLU-PP-332 Work? Mechanism of Action, Per the Research

SLU-PP-332 is a small synthetic molecule, not a peptide, and the published literature characterises it as an agonist of the estrogen-related receptors (ERRs). This page summarises how researchers have described its mechanism of action, separating what has been demonstrated at the receptor level from what has been inferred from downstream physiology in animal and cell models. This page is for educational purposes only and is not medical advice; consult a licensed physician before making any health decisions.

The receptor target: ERRα, ERRβ and ERRγ

The estrogen-related receptors are a family of three nuclear receptors (ERRα, ERRβ, ERRγ) that share structural similarity with the estrogen receptors but do not bind estrogen. They are classified as orphan receptors because no endogenous hormone ligand has been definitively assigned to them, and they are described as constitutively active, their ligand-binding domains adopt an active conformation and recruit coactivator proteins, most notably the PGC-1 family, without a hormone trigger.

Against that background, the work on SLU-PP-332 is notable because it describes a synthetic ligand that increases, rather than blocks, ERR transcriptional activity. The 2023 characterisation study described SLU-PP-332 as a synthetic ERRα/β/γ agonist and reported that it induced an acute aerobic exercise-like response in mouse skeletal muscle (https://pubmed.ncbi.nlm.nih.gov/36988910/). Because it engages all three subtypes rather than one, later papers refer to the chemotype as a pan-ERR agonist (https://pubmed.ncbi.nlm.nih.gov/37961903/).

What "agonist" means for a constitutively active receptor

For a receptor that already signals at baseline, an agonist is understood to stabilise the active conformation and enhance coactivator recruitment, raising transcription of target genes above the constitutive set point. Medicinal chemistry work that optimised the SLU-PP-332 scaffold reported that structural modification of the series altered ERR engagement and provided insight into estrogen-related receptor signalling (https://pubmed.ncbi.nlm.nih.gov/41850449/). That chemistry programme also produced related analogues, including the orally active agonist SLU-PP-915, which researchers reported enhanced aerobic exercise capacity in rodent work (https://pubmed.ncbi.nlm.nih.gov/41421047/).

Established mechanism versus proposed mechanism

It is useful to distinguish three layers: (1) the molecular interaction, (2) the transcriptional programme it switches on, and (3) the whole-organism physiology that follows. Only the first two have been examined directly in the molecular pharmacology; the third is inferred from animal phenotypes.

Downstream signalling: the oxidative gene programme

ERRs are best known as transcriptional regulators of the mitochondrial and oxidative metabolism gene network, enzymes of the tricarboxylic acid cycle, oxidative phosphorylation complexes, and fatty acid uptake and β-oxidation. Pharmacologically pushing this network is the proposed basis for calling the compound an exercise mimetic, a framing used in a review of ERRα/β/γ activation as an exercise-mimetic strategy and its potential therapeutic applications (https://pubmed.ncbi.nlm.nih.gov/42024694/).

The clearest mechanistic evidence comes from the original mouse work: researchers reported that the acute transcriptional response in skeletal muscle resembled the response to aerobic exercise and that it required ERRα, since the effect was lost in the absence of that subtype, and the same study reported increased exercise capacity in treated mice (https://pubmed.ncbi.nlm.nih.gov/36988910/). The receptor-dependence experiment matters mechanistically: it links the observed phenotype to the intended target rather than to an off-target effect.

Cardiac tissue

In heart failure models, a 2024 report in Circulation described pan-ERR agonists ameliorating heart failure through enhanced cardiac fatty acid metabolism and improved mitochondrial function (https://pubmed.ncbi.nlm.nih.gov/37961903/). The proposed mechanism there is substrate-level: a failing heart is often described as energy-starved, and the study framed restoration of fatty acid oxidation capacity as the route by which ERR agonism altered the phenotype (https://pubmed.ncbi.nlm.nih.gov/37961903/).

Kidney tissue

A 2023 study in aging kidney reported that estrogen-related receptor agonism reversed mitochondrial dysfunction and reduced inflammation (https://pubmed.ncbi.nlm.nih.gov/37717940/). That combination, a mitochondrial readout plus an inflammatory readout, is consistent with the broader proposal that ERR-driven mitochondrial quality control indirectly modulates inflammatory signalling, though the study design reported the association rather than isolating the causal step (https://pubmed.ncbi.nlm.nih.gov/37717940/).

Whole-body metabolism

A 2024 paper in the Journal of Pharmacology and Experimental Therapeutics reported that a synthetic ERR agonist alleviated features of metabolic syndrome in a rodent model (https://pubmed.ncbi.nlm.nih.gov/37739806/). Mechanistically, the proposal is that increased oxidative capacity in muscle and other metabolically active tissues shifts substrate handling; the study reported the metabolic outcome, and the inference back to the receptor rests on the pharmacology established in the earlier characterisation work (https://pubmed.ncbi.nlm.nih.gov/36988910/).

Skeletal muscle and disuse

A 2025 pilot study examined whether targeting ERRs could counteract age-related muscle atrophy associated with physical inactivity (https://pubmed.ncbi.nlm.nih.gov/40692696/). Pilot studies are, by design, exploratory: the authors described it as a pilot, and such work generates hypotheses about mechanism rather than confirming them (https://pubmed.ncbi.nlm.nih.gov/40692696/).

Pharmacokinetics, metabolism and detection

How a molecule behaves after administration is part of its practical mechanism. An in vitro metabolism study characterised SLU-PP-332 and SLU-PP-915 as novel pan-ERR agonists with doping potential and reported analytical characterisation of the compounds and their metabolism in vitro (https://pubmed.ncbi.nlm.nih.gov/41588687/). Work of that kind is typically undertaken so that anti-doping laboratories can identify markers of use; it is explicitly in vitro and does not describe human pharmacokinetics (https://pubmed.ncbi.nlm.nih.gov/41588687/).

Route of administration is also part of the mechanistic story for this chemical series. The analogue SLU-PP-915 was described as orally active, and researchers reported that it enhanced aerobic exercise capacity in preclinical testing (https://pubmed.ncbi.nlm.nih.gov/41421047/). The existence of optimised follow-on compounds indicates that the original molecule's properties were a target for improvement, which the chemical optimisation study addressed directly (https://pubmed.ncbi.nlm.nih.gov/41850449/).

What the mechanism does not explain

• Subtype selectivity. Because the compound is described as a pan-agonist across ERRα, ERRβ and ERRγ (PMID 37961903), the contribution of each subtype to any given tissue effect is not separable from the whole-animal data, although the skeletal muscle response was reported to be ERRα-dependent (PMID 36988910).
• Tissue distribution. ERRs are expressed across many oxidative tissues, so a systemically administered pan-agonist would not act on one organ in isolation; the published models examined muscle, heart and kidney separately (PMID 37717940).
• Human translation. The verified literature consists of in vitro assays, rodent models and a pilot study; a review framed ERR activation as an exercise mimetic with potential therapeutic applications rather than demonstrated clinical use (PMID 42024694).
• Long-term consequences. Chronically elevating a transcriptional programme that normally fluctuates with activity and feeding is a hypothesis-generating question that the published work did not resolve.

Tolerability and Adverse Events: What Studies Report

The verified literature summarised here is preclinical and analytical, and it does not contain controlled human safety trials. The metabolic syndrome report described alleviation of metabolic syndrome features in a rodent model rather than a formal toxicology programme (https://pubmed.ncbi.nlm.nih.gov/37739806/), and the heart failure study likewise reported efficacy endpoints relating to cardiac fatty acid metabolism and mitochondrial function (https://pubmed.ncbi.nlm.nih.gov/37961903/). The in vitro metabolism work addressed analytical detection and metabolic fate rather than clinical tolerability (https://pubmed.ncbi.nlm.nih.gov/41588687/). Readers evaluating mechanism should treat the absence of human adverse-event data as an open question, not as evidence of safety.

Regulatory status in brief

SLU-PP-332 is an investigational research chemical. It is not an approved medicine in the United States or the European Union, and compounds in this series have been discussed in the anti-doping literature precisely because they are not authorised therapeutics; the in vitro characterisation study framed both SLU-PP-332 and SLU-PP-915 as agents with doping potential (https://pubmed.ncbi.nlm.nih.gov/41588687/).

Summary of the mechanism as published

1. SLU-PP-332 binds and activates the estrogen-related receptors ERRα, ERRβ and ERRγ, a family of constitutively active orphan nuclear receptors (PMID 36988910).
2. Receptor activation increases transcription of mitochondrial, oxidative-phosphorylation and fatty acid oxidation genes, which the original study reported as an acute exercise-like signature in mouse skeletal muscle (PMID 36988910).
3. In disease models, researchers reported downstream changes in cardiac energetics (PMID 37961903), renal mitochondrial function and inflammation (PMID 37717940) and systemic metabolic parameters (PMID 37739806).
4. Chemical optimisation produced related pan-ERR agonists, including an orally active analogue reported to enhance aerobic exercise capacity (PMID 41421047, PMID 41850449).

References

• Synthetic ERRα/β/γ Agonist Induces an ERRα-Dependent Acute Aerobic Exercise Response and Enhances Exercise Capacity (ACS Chemical Biology, 2023)
• Estrogen-Related Receptor Agonism Reverses Mitochondrial Dysfunction and Inflammation in the Aging Kidney (The American Journal of Pathology, 2023)
• A Synthetic ERR Agonist Alleviates Metabolic Syndrome (The Journal of Pharmacology and Experimental Therapeutics, 2024)
• Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function (Circulation, 2024)
• Targeting ERRs to counteract age-related muscle atrophy associated with physical inactivity: a pilot study (Frontiers in Physiology, 2025)
• An orally active estrogen receptor-related receptor agonist, SLU-PP-915, enhances aerobic exercise capacity (The Journal of Pharmacology and Experimental Therapeutics, 2026)
• In Vitro Metabolism and Analytical Characterization of SLU-PP-332 and SLU-PP-915: Novel Pan-ERR Agonists With Doping Potential (Rapid Communications in Mass Spectrometry, 2026)
• Chemical optimization of the exercise mimetic SLU-PP-332 enables insight into estrogen-related receptor signaling (International Journal of Biological Macromolecules, 2026)
• Pharmacological Activation of ERRα/β/γ as an Exercise Mimetic: Potential Therapeutic Applications (Revista Médica de Chile, 2026)